AG
NMRA icon

Artal Group’s Neumora Therapeutics NMRA Stock Holding History

Artal Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,824,052
Closed -$27.8M – 62
2024
Q2 		$27.8M Sell
2,824,052
-100,000
-3% -$1.03M 0.71% 17
2024
Q1 		$40.2M Buy
2,924,052
+371,350
+15% +$6M 1.02% 15
2023
Q4 		$43.5M Sell
2,552,702
-250,000
-9% -$3.07M 1.45% 13
2023
Q3 		$39.5M Buy
+2,802,702
New +$35M 1.7% 12

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Artal Group's NMRA Position: Q3 2024 in Review

Artal Group sold out of Neumora Therapeutics (NMRA) in Q3 2024, closing a stake of 2,824,052 shares — an estimated $27.8M sold.

Artal Group first reported a position in NMRA in Q3 2023 and held it in 4 quarters. The position peaked at $43.5M in Q4 2023. 104 funds tracked by Wall St. Rank hold NMRA as of Q3 2024.

  • Artal Group reported no remaining Neumora Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 2,824,052 Neumora Therapeutics shares in Q3 2024, an estimated $27.8M.
  • Artal Group first reported a position in Neumora Therapeutics in Q3 2023 and held it in 4 quarters.
  • Artal Group's Neumora Therapeutics position peaked at $43.5M in Q4 2023.
  • 104 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.